Payment overview · 2025
General Payments
$76.13
4 reported records · 2 companies
Healthcare provider profile · identity verified
Craig Elbert Webb, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WILMINGTON, NC · NPI 1124129663
Verified facts
What the public records show
CMS Open Payments records show Craig Elbert Webb, P.A. received $76.13 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 80.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.93 | 80.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.20 | 20.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.13 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.93 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 103 |
| Furosemide | Furosemide | 364 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 77 |
| Gabapentin | Gabapentin | 312 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 83 |
| Losartan Potassium | Losartan Potassium | 265 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 60 |
| Lisinopril | Lisinopril | 229 | 59 |
| Alendronate Sodium | Alendronate Sodium | 206 | 55 |
| Metformin Hcl | Metformin Hcl | 199 | 49 |
| Potassium Chloride | Potassium Chloride | 176 | 46 |
| Omeprazole | Omeprazole | 162 | 45 |
| Trazodone Hcl | Trazodone Hcl | 162 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 34 |
| Glipizide Er | Glipizide | 139 | 33 |
| Prednisone | Prednisone | 137 | 83 |
| Simvastatin | Simvastatin | 132 | 37 |
| Allopurinol | Allopurinol | 124 | 31 |
| Methocarbamol | Methocarbamol | 122 | 28 |
| Warfarin Sodium | Warfarin Sodium | 115 | 37 |
| Alprazolam | Alprazolam | 112 | 18 |
| Eliquis | Apixaban | 103 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 15 |
| Montelukast Sodium | Montelukast Sodium | 87 | 24 |
| Sertraline Hcl | Sertraline Hcl | 84 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 67 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Famotidine | Famotidine | 66 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Finasteride | Finasteride | 65 | 19 |
| Meloxicam | Meloxicam | 64 | 19 |
| Ozempic | Semaglutide | 64 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Carvedilol | Carvedilol | 63 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 14 |
| Jardiance | Empagliflozin | 60 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 15 |
| Glimepiride | Glimepiride | 58 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 18 |
| Donepezil Hcl | Donepezil Hcl | 55 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 12 |
| Celecoxib | Celecoxib | 53 | 17 |
| Clonidine Hcl | Clonidine Hcl | 51 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 22 |
| Metformin Hcl Er | Metformin Hcl | 50 | 14 |
| Spironolactone | Spironolactone | 50 | 14 |
| Atenolol | Atenolol | 49 | 15 |
| Tramadol Hcl | Tramadol Hcl | 49 | 12 |
| Valacyclovir | Valacyclovir Hcl | 49 | 15 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Topiramate | Topiramate | 45 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Ibuprofen | Ibuprofen | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 15 |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 18 |
| Estradiol | Estradiol | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 19 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Felodipine Er | Felodipine | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 13 |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nefazodone Hcl | Nefazodone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.13 · 4 records | AstraZeneca Pharmaceuticals LP | BREZTRI, MOUNJARO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error